Preferred Label : Luvometinib;
NCIt synonyms : MEK Inhibitor FCN-159; MEK 1/2 Inhibitor FCN-159;
NCIt definition : An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K,
MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration,
luvometinib selectively binds to and inhibits the activity of MEK1 and MEK2, preventing
the activation of MEK1/2-dependent effector proteins and transcription factors, which
may result in the inhibition of growth factor-mediated cell signaling and tumor cell
proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key
roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth.
This pathway is often dysregulated in a variety of tumor cell types through BRAF,
KRAS and NRAS mutations.;
UNII : B2DYT4V89X;
CAS number : 2739690-43-6;
Molecule name : FCN-159; FCN 159;
NCI Metathesaurus CUI : CL1406509;
Origin ID : C172382;
UMLS CUI : C5417912;
Semantic type(s)
- concept_is_in_subset
- has_target
